This document is published by the XX[CHROME] Medical Office as an internal educational reference on the peptides catalogued for supervised use. It exists to inform clinical reasoning — not to replace it.

• Purpose. A structured primer on what peptides are, how they signal, how they are reconstituted, stored and administered, and how the catalogued compounds are positioned.
• Scope. Limited to compounds dispensed by XX[CHROME] under licensed oversight. No GLP-1 weight-loss agents or estrogen modulators are dispensed.
• Standing. Educational and informational only. Nothing herein constitutes diagnosis, treatment, or a guarantee of outcome. Individual response varies.
• Use. Every protocol requires intake, laboratory work, and an explicit prescription from the supervising clinician before dispensation.

XX[CHROME] — Los Angeles · Office Monograph

• Understand what peptides are and how they differ from traditional pharmaceuticals.
• Learn the fundamental mechanisms of peptide action.
• Master practical aspects — reconstitution, storage, and administration routes.
• Examine specific catalogued peptides by clinical application — weight, repair, aesthetics, cognition.
• Explore synergistic combinations and baseline clinical protocols.
• Support confident, safe integration of peptide therapy under supervision.

Clinical preparation · partner lab

• Definition. Short chains of amino acids — typically <50 — linked by peptide bonds.
• Signaling. Endogenously produced; act as hormones, neurotransmitters, growth factors.
• Size. Smaller than proteins — often better absorption or more specific targeting.
• Specificity. Keys fitting specific cellular receptor locks, initiating downstream effects.
• Analogy. Precise biological messengers carrying specific instructions to cells.

• Receptor binding. The primary mechanism. Peptides bind specific receptors on or within cells, triggering a defined cascade of molecular responses.
• Signal transduction. Binding initiates a chain of intracellular events via the signal-transduction pathway.
• Targeted effects. Specificity yields targeted physiological responses — hormone release, reduced inflammation, cell growth.
• Vs. pharmaceuticals. Often modulate existing pathways rather than introducing foreign mechanisms — fewer off-target effects when used appropriately.
• Bioregulators. Tend to restore normal function rather than push systems beyond physiological limits.

• Historical context. Insulin — a peptide hormone — was among the first peptide therapies.
• Regulatory categories. Therapeutic (FDA-approved, e.g. insulin, GLP-1 agonists), research peptides, and wellness peptides.
• Sourcing. From reputable labs with third-party testing — XX[CHROME] dispenses small-batch under clinician review.
• Contraindications. Crucial to screen patients thoroughly; covered per peptide.
• Side effects. Often administration-related or tied to intended action. Start low, go slow.
• Informed consent. Essential — discuss benefits, risks, alternatives, and the research nature of some compounds.

Small-batch clinical apothecary

• Subcutaneous (SubQ). Most common route. Sites: abdomen (avoid 2″ around navel), thighs, buttocks, upper-arm fat — rotate. 45–90° pinch, slow inject, gentle pressure. Insulin syringes (29–31 ga, ½″ or 5⁄16″).
• Intravenous (IV). Primarily NAD+. Requires proper setup and trained personnel. Slow infusion (e.g. 2–4 h / 500 mg) manages flushing & chest pressure; push IV once tolerance is established.
• Intramuscular (IM). Less common for these compounds; possible for others.
• Oral / Nasal. Not relevant for the current set, though Selank has nasal versions.

SubQ kit · reconstitution & dosing

• 01 — Weight Management & Metabolic Health. tirzepatide · 5-amino-1mq · mots-c
• 02 — Tissue Repair, Regeneration & Aesthetics. bpc-157 · bpc-157/tb-500 · ghk-cu
• 03 — Cognitive Enhancement & Mood Regulation. selank
• 04 — Cellular Health, Energy & Longevity. nad+ — underpins the others

XX[CHROME]Tirzepatidedual-action incretin mimeticXX-W01 · LA

A synthetic analog of human GIP with GLP-1 receptor activity — a powerful tool for blood-sugar control and significant weight loss.

• GLP-1 agonist. ↑ glucose-dependent insulin, ↓ glucagon, slows gastric emptying (satiety), reduces appetite centrally.
• GIP agonist. Enhances insulin secretion, may improve insulin sensitivity and fat-metabolism regulation — synergistic glucose & weight effects vs GLP-1 alone.
• Indications. Weight loss, type-2 diabetes, potential metabolic-syndrome benefit.
• Contraindications. Personal/family MTC, MEN 2, pancreatitis history, severe gastroparesis, pregnancy/breastfeeding, hypersensitivity.
• Side effects. Primarily GI — nausea, vomiting, diarrhea, constipation. Lean-mass loss is common (protein + training essential). Hypoglycemia risk with other agents.

XX[CHROME]MOTS-cmitochondrial-derived peptideXX-W02 · LA

Encoded within mitochondrial DNA; regulates metabolic function — glucose utilization, insulin sensitivity, energy production.

• Mechanism. Modulates cellular metabolism via mitochondrial function; ↑ insulin sensitivity & glucose uptake (AMPK); promotes fatty-acid oxidation; neuroprotective & anti-inflammatory in preclinical models; ↑ endurance.
• Indications. Insulin sensitivity, weight-management adjunct, exercise performance, mitochondrial/longevity support; stacks with Tirzepatide.
• Contraindications. Active cancers (theoretical, caution), pregnancy/breastfeeding, severe kidney/liver disease (limited data).
• Side effects. Generally well tolerated — mild injection-site or GI; hypoglycemia unlikely unless combined with glucose-lowering agents.

XX[CHROME]5-Amino-1MQNNMT inhibitorXX-W03 · LA

A small-molecule inhibitor of NNMT — an enzyme upregulated in adipose tissue in obesity and linked to metabolic dysfunction.

• Mechanism. Inhibits NNMT activity; ↑ intracellular NAD+ in adipose (and potentially muscle); may ↑ energy expenditure & lipolysis; preserves muscle in deficit; ↑ insulin sensitivity in preclinical models.
• Indications. Fat-loss-focused weight management; muscle preservation during weight loss (crucial with Tirzepatide); insulin sensitivity; potential maintenance therapy post-Tirzepatide.
• Contraindications. Pregnancy/breastfeeding, active cancer (theoretical), severe liver/kidney disease (limited data).
• Side effects. Generally well tolerated — mild headache, fatigue, GI; possible sleep disturbance if late; HR increase noted in some protocols.

XX[CHROME]BPC-157body protection compoundXX-R01 · LA

A synthetic peptide fragment derived from gastric juice — potent cytoprotective and regenerative properties across tissues.

• Mechanism. Angiogenesis (new vessels for healing); growth-factor modulation (VEGF, EGF); NO-system modulation; collagen synthesis; anti-inflammatory (↓ TNF-α, IL-6); cytoprotection vs NSAIDs/toxins.
• Indications. Post-surgical healing (lipo, breast, aesthetics); musculoskeletal — tendonitis, sprains, tears; gut health (gastritis, ulcers, IBD); wound healing; joint pain & arthritis.
• Contraindications. Active cancers/malignancies (angiogenic, theoretical), pregnancy/breastfeeding.
• Side effects. Remarkably well tolerated — mild, temporary injection-site reaction; rare mild nausea/light-headedness.

XX[CHROME]BPC-157 / TB-500structural repair blendXX-R02 · LA

Combines BPC-157's foundational healing with TB-500's actions on cell migration and actin regulation — faster, more comprehensive repair for structural tissues.

• TB-500. Synthetic Thymosin Beta-4 (Tβ4) — enhanced cell migration, faster remodeling, improved flexibility, broader anti-inflammatory action.
• Enhanced cell migration — accelerates repair-cell movement (endothelial, keratinocytes, fibroblasts, stem cells).
• Accelerated wound healing across skin, muscle, tendon, ligament, eye, heart; angiogenesis; reduced scarring/fibrosis; increased flexibility; cardio/neuroprotective potential.

XX[CHROME]GHK-Cucopper tripeptide complexXX-R03 · LA

A naturally occurring copper-peptide complex found in human plasma — remarkable skin remodeling, wound healing, anti-inflammatory and hair-growth properties.

• Mechanism. ECM remodeling — collagen, elastin, proteoglycans, GAGs; modulates MMPs to clear old/damaged tissue; wound healing (↓ scar, ↑ angiogenesis); hair growth (follicle enlargement, ↑ VEGF).
• Indications. Post-procedure healing (laser, microneedling, peels, surgery); skin rejuvenation — firmness, elasticity, fine lines, hyperpigmentation; chronic wounds/burns; androgenetic alopecia; acne/rosacea calming.
• Contraindications. Wilson's disease (copper metabolism), active malignancy/cancer (growth-promoting caution), pregnancy/breastfeeding.
• Side effects. Well tolerated topically. Injections: mild local reaction; possible temporary blue tint at site (copper) with higher/superficial dosing — usually resolves.

XX[CHROME]Selankanxiolytic · nootropicXX-C01 · LA

A synthetic analog of the endogenous peptide tuftsin — anxiety-reducing and cognitive-enhancing effects without sedation.

• Mechanism. GABAergic modulation (anxiety reduction without benzodiazepine sedation); serotonin/dopamine balance; ↑ BDNF (neuronal survival, neurogenesis, synaptic plasticity); immune modulation under stress.
• Indications. Anxiety reduction (generalized, stress-related); improved stress adaptation; cognitive enhancement (focus, memory, learning); mood stabilization; adjunct for mild depression.
• Contraindications. Pregnancy/breastfeeding; caution with CNS depressants/sedatives (Selank itself non-sedating); active malignancy (general peptide caution).
• Side effects. Very well tolerated, high safety profile in trials. Rare/mild: headache, dizziness, nausea; injection-site reactions; insomnia listed in combo doc.

XX[CHROME]NAD+the master coenzymeXX-L01 · LA

A critical coenzyme in every cell — essential for hundreds of metabolic processes, particularly ATP production. Levels decline with age.

• Mechanism. Central redox electron-carrier in glycolysis & Krebs cycle (ATP); required cofactor for PARPs (DNA repair); fuel for sirtuins ("longevity genes"); role in neurotransmitter synthesis.
• Indications. Longevity & anti-aging; energy enhancement; cognitive support (neuroprotective); metabolic health; addiction-recovery support; foundational support enhancing other regenerative therapies.
• Contraindications. Active cancer (theoretical — oncologist consult); pregnancy/breastfeeding; severe cardiovascular disease / uncontrolled hypertension; uncontrolled diabetes/metabolic disorders (monitor during IV).

• Individualization. Adjust based on patient response, tolerance, goals, and budget.
• Cycling. Many peptides benefit from on/off periods to prevent receptor downregulation (BPC, GHK, Selank, 5-Amino). Tirzepatide often continuous while needed; NAD+ cycled or for maintenance.
• Loading phases. Some protocols use higher initial doses, then drop to maintenance (e.g. NAD+ first-time use).
• Monitoring. Clinical assessment, patient feedback, relevant labs (glucose, lipids, thyroid, kidney/liver, inflammatory or hormone markers).
• Documentation. Meticulous records of peptides, doses, frequency, response, and adverse effects.

Monitoring · documentation · review